A selection of Lancet research highlights for September 21, 2019

Lancet: Methyldopa, nitrospy and Raboril for pregnancyhypertensiontreatmentDOI: https://doi.org/10.1016/S0140-6736 (19) 31282-6hypertensionis the most common disease in pregnancyRecently, researchers compared the efficacy and safety of three oral drugs, Rabbeol, nitrobenzene flat coagulants and methyldopa, for the treatment of severe hypertension during pregnancy18 years of age and 28 weeks pregnant with severe hypertension pregnant women participated in the study, randomly received 10 mg of oral nitrophen, 200 mg oral labelloor or 1000 mg methyl dopaThe main outcomes of the study were blood pressure control within 6 hours (defined as systolic pressure of 120-150mmHg, diastolic pressure of 70-100mmHg) and adverse outcomes894 women were treated at random: 298 (33 per cent) were assigned to receive nitrospyl, 295 (33 per cent) were assigned to Labetanello and 301 (33 per cent) were assigned to receive methyldobaThe main endpoint compliance rate for women in the nitrobenzene group was significantly higher than that of the methyl dopa group (249 (84%) vs 230 (76%), however, there was no difference in the main results of the nitrospyl flat group and the Laberol group (249 (84%) vs 228 cases ,77%), and the main results of labethalloando and methyl dopa group were not any different (p.80)In this study, 7 cases of serious adverse reactions (1% of newborns): 1 case (1%) of women in the Labetorol group had post-natalepilepsy, 6 cases (1%) of newborns (1 newborn in the nitrosyl group, 2 in the Labetaro group and 3 newborns in the methyldoba group) were stillborn: The risk of medium-and long-term cardiovascular events in cancer survivors increased DoI: https://doi.org/10.1016/S0140-6736(19) 31674-5 Researchers recently assessed the long-term risk of cardiovascular in cancer populations by several UK databases, examining the of 20 most common cancer survivors The main endpoint of the study was a range of cardiovascular disease risk 126,120 cancer patients were involved and paired with 630,144 control groups Compared to the control group, 18 tumor survivors had an increased risk of venous thrombosis embolism, and adjusted risk ratio (HRs) ranged from 1.72 to pancreatic cancer patients Over time, HRs declined, but remained high five years after diagnosis The researchers observed an increased risk of heart failure or cardiomyopathy in 10 of the 20 types of cancer, with adjusted HR: non-Hodgkin lymphoma 1.94, leukemia 1.77, multiple myeloma 3.29, esophageal cancer 1.96, lung cancer 1.82, and 1.59 An increased risk of arrhythmia, arrhythmis, coronary artery disease, stroke, and valve heart disease was also observed in a variety of cancers, including hematologic malignant tumors HRs for heart failure or cardiomyopathy and venous thromboembolism are greater in patients with non-basic cardiovascular disease sandin : Fremangezumab for stubborn migraines prevention DOI: https://doi.org/10.1016/S0140-6736(19) 31946-4 Researchers recently examined the effectiveness and tolerance of fully humanized CG antibody Fremantzumab in patients who have been treated with unresponsive migraines this phase III study recruited 838 patients between the ages of 18 and 70 with intermittent or chronic migraine, who received 2-4 types of migraine prevention drugs over the past 10 years, including 329 cases of occasional migraines (39%), 509 cases of chronic migraines (61%), divided into placebo group (n?279), quarterfreezumab group (n?276) or fremanzumab group (n.276) or monthly Fremanzumab group During the 12 weeks, the average number of migraine days per month in the treatment group decreased significantly compared to placebo (compared to placebo, the quarterly group had a difference of -3.1 lSM and the monthly group was -3.5) The difference in the rate of adverse events between groups was not significant : Octosic brain stroke and adverse prognosis risk DoI: https://doi.org/10.1016/S0140-6736(19) 31795-7 in non-surgical settings, hidden stroke is more common than dominant stroke and is associated with cognitive decline Recently, researchers examined the relationship between hidden stroke during peroperative surgery (i.e., in non-cardiac patients with no clinical stroke symptoms, acute cerebral infarction found in postoperative MRI) and cognitive decline in the 1 year after surgery 1,114 participants, 78 (7%) had hidden strokes In one year of follow-up, 29 (42%) of the 69 patients with hidden stroke experienced cognitive decline, and 274 of the 932 patients without hidden stroke had cognitive decline (29%, OR.1.98) Hidden stroke was associated with postoperative delirium (HR s 2.24, 6% increasein absolute risk) and the risk of stroke or transient cerebral ischemia (HR s 4.13, an increase dyselucious risk of 3%) MedSci Source: MedSci Original